FibroGen exclusively in-licenses HiFiBiO's Galectin-9 program and obtains an exclusive option to their CXCR5 and CCR8 programs.
Under the terms of the agreement, FibroGen will make a $25 million upfront payment to HiFiBiO and payments upon option exercise.
In addition, HiFiBiO may receive up to a total of an additional $1.1 billion in milestone payments across all three programs.
HiFiBiO will also be eligible to receive royalties based upon worldwide net sales.
The lead product candidate in the Galectin-9 program is expected to enter clinical development in the Q1 of 2023.
The lead candidates from the CXCR5 and CCR8 programs will enter the clinic by mid-2023.
Price Action: FGEN shares closed at $25.84 on Wednesday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.